Sending Office: Honorable Doug Collins
Co-Sponsor HR 1316, the Prescription Drug Price Transparency Act
115th Co-sponsors (43): Robert Aderholt, Rick Allen, Brian Babin, Don Bacon, Lou Barletta, Rod Blum, Mo Brooks, Bradley Byrn, Buddy Carter, Kevin Cramer, Rick Crawford, Elijah Cummings, John Duncan, Drew Ferguson, Mike Gallagher,
Tom Graves, Morgan Griffith, Gregg Harper, Vicky Hartzler, Jody Hice, Walter Jones, Peter T. King, James Langevin, David Loebsack, Roger Marshall, Dan Newhouse, Cathy McMorris Rodgers, Steven Palazzo, Collin Peterson, Jamie Raskin, Kathleen Rice, David Roe,
Mike Rogers, David Rouzer, Tim Ryan, John Sarbanes, Austin Scott, Elise Stefanik, Filemon Vela, Peter Welch, Bruce Westerman, Robert Wittman, David Young.
Supporting Organizations: National Community Pharmacists Association, National Association of Specialty Pharmacy, Community Oncology Alliance, American Pharmacists Association, US Oncology Network, Center for Medicine in the Public Interest,
American Academy of Dermatology, American College of Rheumatology, Arthritis Foundation, Coalition of State Rheumatology Organizations, Global Healthy Living Foundation, Lupus and Allied Diseases Association, National Organization of Rheumatology Managers,
Rheumatology Nurses Society, Alliance for Transparent and Affordable Prescriptions, American Pharmacy Cooperative, Inc.
Pharmacy Benefit Managers (PBMs) keep many of their practices – including the reimbursement rate for prescription drugs – shrouded in secrecy. In doing so, PBMs are able to manipulate the reimbursement rates for pharmacies in order to maximize their profit
margin. PBMs can and do fail to regularly update Maximum Allowable Costs (MAC) lists in order to charge plan sponsors and patients more, while reimbursing pharmacies less.
I have introduced H.R. 1316, the Prescription Drug Price Transparency Act, to help address this issue. H.R. 1316 provides for greater transparency of PBMs that administer federal programs (Medicare Part D, Medicare Advantage Part D, TRICARE, and FEHBP).
Thirty-three states have passed and implemented PBM transparency legislation similar to H.R.1316. Many of these states have found immense success through the implementation of this legislation, in some cases saving over $200 million per year.
Please join me in helping to promote transparency and accountability by cosponsoring the Prescription Drug Price Transparency Act.
To become a cosponsor of this legislation, or if you have any questions, please contact Daniel Ashworth at
email@example.com or x65221.
Georgia’s Ninth Congressional District
e-Dear Colleague version 2.0